Podiatry Chairs Market Segmentation and Product Types

 The size of the global podiatry chairs market was estimated at USD 1.1 billion in 2023 and is anticipated to reach USD 1.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030. Factors driving market growth include the rising prevalence of foot disorders, advancements in podiatry chair technology, increasing demand for diabetic foot care, and a heightened focus on foot health awareness.

 

An article published by AGS Health in the Aging Foundation in February 2023 highlighted that foot pain significantly impacts mobility, potentially leading to complications such as weight gain, muscle weakness, and impaired heart health. It is estimated that up to 87% of individual’s experience foot pain at some stage in their lives due to various reasons. Among older adults, approximately one-third report experiencing foot pain, stiffness, or discomfort.

The growing demand for diabetic foot care is a crucial driver of market expansion. According to a November 2023 article from the American Medical Association, diabetic foot ulcers are a prevalent complication for those with type 1 or type 2 diabetes, affecting nearly one-third of diabetic patients throughout their lives. Globally, around 18.6 million individuals, including 1.6 million in the U.S. alone, suffer from these ulcers each year. With nearly half of these ulcers becoming infected and about 20% of those infections resulting in partial or full foot amputations, the need for specialized diabetic foot care is increasing. This demand propels the market for podiatry chairs as healthcare providers seek advanced equipment to manage and treat diabetic foot conditions effectively.

Key Market Trends & Insights

• North America held the largest share of the podiatry chairs market at 34.5% in 2023, driven by the increasing incidence of foot disorders, the rising prevalence of diabetic foot ulcers (DFU), product launches, regulatory approvals, and advanced healthcare infrastructure.
• The U.S. represented the largest share of North America's podiatry chairs market in 2023, with growth fueled by the rising prevalence of foot-related conditions and a high incidence of sports-related foot injuries.
• The electric segment dominated the product category with over 61.0% of the market share in 2023, owing to technological advancements, strategic initiatives by key players, and the increasing occurrence of foot disorders. Electric chairs provide advanced features and flexibility, allowing for easy adjustments to height, backrest, and leg support at the touch of a button.
• In terms of end use, the hospitals segment accounted for over 41.1% of the market share in 2023, as hospitals are experiencing an increase in patients with complex foot conditions like diabetic foot ulcers, severe arthritis, and vascular issues, necessitating advanced treatment options.

 

Order a free sample PDF of the Podiatry Chairs Market Intelligence Study, published by Grand View Research.

 

Market Size & Forecast

• 2023 Market Size: USD 1.1 Billion
• 2030 Projected Market Size: USD 1.8 Billion
• CAGR (2024-2030): 7.4%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Prominent players in this industry include Medtronic, Abbott, and Boston Scientific Corporation. Their strategies focus on understanding the strengths and weaknesses of major market participants, anticipating future trends, opportunities, and challenges, and making informed decisions based on insights into emerging technologies and evolving consumer preferences. Emerging players in the podiatry chairs market include Lepu Medical and Microport Scientific Corporation.

Key Players

• Angelus Medical and Optical
• Medline
• Midmark Corporation
• Hill Laboratories
• ARIA Chairs
• Soma Tech Intl.
• Lemi MD
• Gharieni Group
• TitanMed
• Namrol Medical S.L.

 

Conclusion

The global podiatry chairs market is poised for significant growth, driven by increasing foot disorder prevalence, the demand for diabetic foot care, and advancements in chair technology. As healthcare providers seek innovative solutions to manage complex foot conditions, the market is expected to expand, particularly in North America and the rapidly growing Asia Pacific region. Key players are strategically positioning themselves to capitalize on emerging opportunities, ensuring that high-quality podiatry chairs meet the evolving needs of patients and healthcare facilities.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Peanut Allergy Treatment Market Will have Impact of Oral Immunotherapy on Patient Care

The global peanut allergy treatment market was valued at USD 536.8 million in 2024 and is anticipated to grow to USD 1,461.5 million by 2033, achieving a CAGR of 11.43% from 2025 to 2033. This growth is being driven by the increasing prevalence of peanut allergies and advancements in therapeutic options. A notable trend is the shift from avoiding allergens to proactive treatments such as oral immunotherapy and biologics, which enhance patient quality of life. The market is evolving with new regulatory approvals and research and development efforts focused on safer and more effective solutions. This growth indicates a vibrant industry that addresses a significant health concern and presents vast opportunities for innovation.

 

Palforzia, the first oral immunotherapy for peanut allergies approved by the FDA, marks a crucial development in allergy treatment. Unlike traditional avoidance methods, Palforzia employs a controlled desensitization strategy to lessen the severity of allergic reactions. This therapy has shown improved clinical results and has been widely adopted, especially in North America, where it is expected that over 60% of eligible pediatric patients will transition to such immunotherapies by 2024. The market's expansion is also supported by heightened awareness of food allergies and advancements in diagnostic technologies, which stimulate the demand for novel and effective treatment options.

 

Key Market Trends & Insights

• North America peanut allergy treatment industry dominated globally in 2024, capturing a substantial 37.31% of global revenue share. This leadership is primarily attributed to the United States, which accounted for approximately 85% of the region's market share. The U.S. market is bolstered by advanced healthcare infrastructure, high levels of allergy awareness, and robust regulatory support from agencies like the FDA.
  
  
• By drug class, epinephrine held the largest share in the market with 46.63% in 2024, emphasizing its role as the primary emergency solution for anaphylaxis. Antihistamines are widely used for managing mild reactions, while immunotherapies, including Palforzia, show potential for long-term allergy management.
  
  
• By route of administration, injectable treatment dominated the market in 2024, holding 61.72% share, primarily due to its rapid effectiveness in emergency situations. Epinephrine injections remain the gold standard for anaphylaxis management, ensuring immediate relief for severe allergic reactions.
  
  
• By distribution channel, hospital pharmacies dominated in 2024 with a 55.46% share, as they handle initial immunotherapy doses under medical supervision and supply epinephrine for emergencies. Their critical role in specialized allergy care ensures their leadership, supported by integration with healthcare systems for high-risk patient management.

 

Market Size & Forecast

• 2024 Market Size: USD 536.8 Million
• 2033 Projected Market Size: USD 1.5 Billion
• CAGR (2025-2033): 11.43%
• North America: Largest Market in 2024
• Asia Pacific: Fastest Growing Market

 

Order a free sample PDF of the peanut allergy treatment Market Intelligence Study, published by Grand View Research.

 

Key Companies & Market Share Insights

Aimmune Therapeutics leads the market with Palforzia, utilizing Nestlé’s resources for global expansion and R&D efforts. DBV Technologies is advancing its Viaskin Peanut product with a focus on non-invasive delivery methods to capture market share. Sanofi remains a leader in emergency treatments with epinephrine auto-injectors, emphasizing distribution capabilities. ALK-Abelló is exploring sublingual options, targeting niche growth. These companies are driving innovation and competition through strategic partnerships and investment in development pipelines.

 

Key Players

• Aimmune Therapeutics (Nestlé Health Science)
• DBV Technologies
• Sanofi
• ALK-Abelló
• Prota Therapeutics
• Camallergy
• Aravax
• Genentech

 

Conclusion

The peanut allergy treatment market is poised for significant growth driven by innovative therapies, increased patient awareness, and expanding access to healthcare solutions. The ongoing research and development efforts, coupled with strategic initiatives from key players, are expected to further enhance treatment options and improve patient outcomes in the coming years.

 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

 

 

Food Allergy Treatment Market Navigating Challenges and Innovations

 The global food allergy treatment market was valued at approximately USD 6,872.9 million in 2024 and is expected to grow to USD 11,332.1 million by 2030, with a compound annual growth rate (CAGR) of 8.3% from 2025 to 2030. This growth is driven by the increasing prevalence of food allergies globally, alongside heightened research and development efforts for new treatments. Additionally, the adoption of innovative biological agents for food allergy treatment and a rise in clinic visits from patients seeking therapy are likely to further propel market growth during the forecast period.

Food allergies, particularly to dairy and peanuts, are increasingly common among children in Western countries. Peanut allergies, which often persist into adulthood, typically begin in early childhood and are associated with more severe reactions compared to other food allergies. Unlike many allergies that may resolve as children grow older, peanut allergies tend to remain throughout life for most individuals.

Historically, managing food allergies has involved strict avoidance of allergens and emergency action plans, including the use of adrenaline auto-injectors. However, the 2018 guidelines from the European Academy of Allergy and Clinical Immunology (EAACI) have recommended Oral Immunotherapy (OIT) as a viable treatment for children as young as 4 to 5 years old. This shift reflects the increasing prevalence of food allergies and emphasizes the need for innovative treatments that can improve management strategies and potentially lessen the severity of allergic reactions.

Key Market Trends & Insights

• North America led the food allergy treatment market in 2024, capturing the largest revenue share of 39.14%. This dominance is attributed to a growing awareness of the significant potential of allergy medications, prompting U.S. companies to invest heavily in their development.

• In terms of allergen type, the peanut segment held the largest revenue share at 20.55% in 2024 and is anticipated to experience the fastest growth rate. This is driven by the increasing prevalence of peanut allergies globally and heightened research and development for new treatments.

• Among drug types, the epinephrine segment accounted for 41.0% of the market share in 2024, as it is the preferred medication for allergic reactions. Its growth is fueled by the rising incidence of food allergies, affecting over 32 million Americans and around 10% of the population in certain Asia-Pacific countries.

• By route of administration, the parenteral segment led with a revenue share of 54.90% in 2024 and is expected to grow at a CAGR of 10.12%. Epinephrine, primarily administered via intramuscular injection into the thigh, is the main treatment for anaphylaxis.

• In terms of end use, hospital pharmacies dominated the market with a revenue share of 55.48% in 2024. The increasing number of hospital pharmacies is a key growth driver, enhancing access to treatments like antihistamines, epinephrine auto-injectors, and newer immunotherapy options.

Order a free sample PDF of the Food Allergy Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 6,872.9 Million
• 2030 Projected Market Size: USD 11,332.1 Million
• CAGR (2025-2030): 8.3%
• North America: Largest market in 2024

Key Companies & Market Share Insights

Key players in the global food allergy treatment industry are actively pursuing strategic initiatives such as mergers and acquisitions, partnerships, and the development of innovative therapies to strengthen their market positions. Prominent companies like Roche, Novartis, and Teva Pharmaceutical are dedicated to advancing their product pipelines to meet unmet treatment needs. These strategic efforts underscore the industry's commitment to enhancing patient outcomes and improving access to treatments within the healthcare landscape.

Key Players

• Sanofi
• Stallergenes Greer
• DBV Technologies
• Vedanta Biosciences, Inc.
• Alladapt Immunotherapeutics, Inc.
• COUR Pharmaceuticals
• Aravax
• Prota Therapeutics Pty Ltd
• Teva Pharmaceutical Industries Ltd.
• F. Hoffman-La Roche Ltd.
• Novartis AG

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global food allergy treatment market will expand due to rising food allergy prevalence and increased research for new treatments. Peanut allergies, especially common among children in Western nations, often persist into adulthood and are linked to severe reactions. Traditional management has focused on allergen avoidance, but recent guidelines now advocate for Oral Immunotherapy (OIT) as a proactive approach for young children. In the U.S., about 1% to 2% of the population, including 6.1 million with peanut allergies, faces this issue, a trend that is also significant in Europe, where approximately 17 million individuals are affected, highlighting the urgent need for effective therapies.

 

Artificial Corneal Implants Market Strategies for Success in a Competitive Environment

 The global artificial corneal implants market was valued at USD 67.9 million in 2022 and is expected to grow to USD 118.4 million by 2030, representing a CAGR of 7.1% from 2023 to 2030. Key factors driving the demand for artificial corneal implants include the rising prevalence of corneal disorders, increased need for corneal transplants, and a shortage of human corneas.

The COVID-19 pandemic adversely affected the artificial corneal implants market. Government-imposed lockdowns and restrictions significantly impacted the industry, as healthcare priorities shifted and professionals focused on managing the virus, leading to the cancellation or postponement of elective surgeries. Additionally, many individuals avoided hospitals as a preventive measure, resulting in a decline in corneal transplant procedures during the pandemic, which negatively influenced the market. However, the market has rebounded rapidly due to a large patient base and a growing number of product launches. Furthermore, increased government investment in R&D within the healthcare sector is expected to further enhance market growth over the forecast period.

Key Market Trends & Insights

• North America held the largest revenue share of 50.9% in the artificial corneal implants market in 2022. This dominance can be attributed to a substantial patient population, the availability of advanced technologies that simplify procedures, and favorable reimbursement policies.

• The hard keratoprosthesis segment led the market, accounting for 87.47% of revenue in 2022, driven by the high adoption of products like Boston Kpro. This artificial cornea is the most commonly used, with continuous design improvements and enhanced postoperative care contributing to better outcomes and increased usage.

• The keratoconus segment held the largest market share of 33.93%, reflecting the growing prevalence of this condition globally. According to the Cancer Research Foundation of America, 1 in 5 keratoconus patients progresses to a stage necessitating a corneal implant for normal vision restoration.

• In terms of implant type, the synthetic segment dominated the market with a revenue share of 93.7% in 2022, largely due to the greater availability of synthetic artificial corneal implants compared to biosynthetic alternatives, leading to higher adoption rates.

Order a free sample PDF of the Artificial Corneal Implants Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 67.9 Million
• 2030 Projected Market Size: USD 118.4 Million
• CAGR (2023-2030): 7.1%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

To solidify their position and enhance their overall market presence, manufacturers are focusing on various strategic initiatives. These include partnerships and collaborations, acquisitions and mergers, expansions, and increased investment in R&D.

Key players are prioritizing the launch of new products and obtaining regulatory approvals in various countries to broaden their product reach and boost revenue. For example, in June 2021, EyeYon received CE Mark approval for its EndoArt, the world's first and only synthetic implant that replaces the human endothelium, following clinical trials that demonstrated its safety and efficacy in treating chronic corneal edema.

Key Players

• FCI Ophthalmics, Inc.
• Beijing Microkpro Medical Instrument Co. Ltd.
• DIOPTEX Medizinprodukte Forschungs
• KeraMed, Inc.
• EyeYon

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global artificial corneal implants market key drivers of demand include the increasing prevalence of corneal disorders, a heightened need for corneal transplants, and a shortage of human corneas. The COVID-19 pandemic negatively impacted the market due to lockdowns and a shift in healthcare priorities, leading to postponed elective surgeries and a decline in corneal transplants. However, the market has since recovered, supported by a large patient base and numerous product launches, alongside increased government investment in R&D expected to further boost growth.

Antacids Market: Emerging Opportunities and Competitive Landscape

 The global antacids market was valued at USD 6.6 billion in 2022 and is anticipated to grow to USD 8.79 billion by 2030, representing a CAGR of 3.7% from 2023 to 2030. One of the primary factors expected to drive market growth during the forecast period is the shift in dietary habits.

The rising incidence of gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive disorders that lead to issues like acidity, digestive problems, and heartburn is also predicted to propel market demand. A study published by the National Institutes of Health (NIH) in 2022 reported that 783.95 million individuals were diagnosed with GERD globally in 2019. From 1990 to 2019, the total number of years lived with disability (YLD) rose by 77.19%, the total number of prevalent cases increased by 77.53%, and the total number of incident cases grew by 74.79%.

Moreover, increasing awareness about GERD is expected to further stimulate market growth. An article from the International Foundation for Gastrointestinal Disorders highlighted that the 23rd Annual GERD Awareness Week took place in November 2022, offering information and support for those affected. Additionally, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) encourages patients experiencing GERD-related symptoms to seek advice from their healthcare providers.

Key Market Trends & Insights

• Regionally, North America leads the antacid market, holding a revenue share of 44.0% in 2022. This dominance is due to a well-established healthcare system and infrastructure, high disposable incomes, and a growing elderly population. Additionally, a rise in digestive disorders is expected to contribute to this trend.

• The Asia Pacific region is anticipated to experience the highest compound annual growth rate (CAGR) of 5.4% during the forecast period, driven by significant unmet clinical needs, the availability of effective treatment options, increasing disposable incomes, and heightened consumer awareness regarding these products.

• By end-use, the market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment accounted for the largest revenue share at 41.5% in 2022, attributed to ease of access, convenience, and the proximity of pharmacy locations. Apollo Pharmacy stands as India’s largest pharmacy chain, boasting over 4,200 stores nationwide in 2022.

• In terms of type, the market is categorized into tablets, liquids, and others. The tablets segment led the market in 2022, with the availability of chewable tablets in various flavors enhancing patient adherence. Tablets also offer precise dosage compared to other forms and are convenient to store.

Order a free sample PDF of the Antacids Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 6.6 Billion
• 2030 Projected Market Size: USD 8.79 Billion
• CAGR (2023-2030): 3.7%
• North America: Largest market in 2022
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

The market features competition among numerous multinational corporations and smaller businesses all vying for a larger share. Key strategies employed by major players include launching new products, expanding geographically, and forming joint ventures.

For instance, in February 2022, GlaxoSmithKline plc (GSK) announced its plan to demerge and list Haleon, a consumer health company. Haleon is set to manage various brands, including the antacids TUMS and ENO. This strategic move aims to help GSK establish a focused global consumer healthcare business through the introduction of Haleon. Haleon's strategy is built upon four main components: portfolio growth and penetration, capitalizing on growth opportunities, robust execution, financial discipline, and responsible business operations.

Furthermore, in June 2022, Wonderbelly, a startup based in Austin, introduced its over-the-counter (OTC) chewable antacid tablets, also named Wonderbelly. These tablets come in flavors like strawberry milkshake, watermelon mint, and fruity cereal. The product is notable for being non-GMO, vegan, and free from talc, synthetic sweeteners, dyes, common allergens, dairy, parabens, gluten, artificial flavors, and preservatives.

Key Players

• GlaxoSmithKline plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd.
• Sanofi
• Reckitt Benckiser Group plc
• Sun Pharmaceuticals Ltd.
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• Procter & Gamble

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

Key growth drivers of global antacids market are changing dietary habits and the rising prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other digestive disorders that cause acidity and heartburn. A 2022 NIH study noted that 783.95 million people were diagnosed with GERD globally in 2019, with significant increases in disability years and prevalent cases from 1990 to 2019. Additionally, heightened awareness about GERD, highlighted during the 23rd Annual GERD Awareness Week in November 2022, is expected to further boost market growth, encouraging patients to consult healthcare providers for symptoms.

 

Ambulance Stretchers Market: Understanding Consumer Preferences and Needs

 The global ambulance stretchers market was valued at USD 2.22 billion in 2023 and is anticipated to reach USD 2.82 billion by 2030, growing at a CAGR of 3.5% from 2024 to 2030. The increasing geriatric population and the rising prevalence of chronic diseases drive a greater demand for emergency medical services. This demographic change significantly boosts the need for ambulance stretchers, as older adults frequently require urgent medical care.

Additionally, the rise in road accidents highlights the necessity for effective ambulance stretchers that ensure timely and efficient patient transport, emphasizing the importance of innovation in stretcher design and functionality. The incorporation of telemedicine features and the development of electric-powered and lightweight models improve the efficiency and safety of patient transport, responding to the demand for enhanced care during emergencies.

Moreover, the post-pandemic emphasis on healthcare has underlined the need for well-equipped ambulances capable of safely transporting patients, especially those with infectious diseases. This trend has led to an increased focus on eco-friendly stretcher designs aimed at minimizing waste and carbon footprints, reflecting a broader commitment to sustainability within the healthcare sector. As healthcare systems continue to progress, the demand for advanced ambulance stretchers that fulfill the needs of both patients and healthcare providers is expected to grow.

Key Market Trends & Insights

• North America ambulance stretchers market dominated the global market in 2023 with a revenue share of 30.5% due to established healthcare systems, technological advancements, and high healthcare spending. Moreover, the increasing occurrence of accidents and chronic illnesses in the area also enhances the need for ambulance stretchers.

• U.S. ambulance stretchers market dominated the North America market with a share of 78.7% in 2023. The U.S. boasts a comprehensive healthcare infrastructure, including hospitals and ambulance services, generating a substantial demand for advanced ambulance stretchers.

• By product, transport stretchers segment dominated the market and accounted for a share of 55.0% in 2023. Transport stretchers are designed for non-emergency patient transfers within healthcare facilities, prioritizing comfort, convenience, and mobility. These stretchers often feature collapsible frames, locking mechanisms, and ergonomic designs, simplifying movement and reducing the burden on healthcare professionals.

• By technology, manual stretchers segment accounted for the largest market revenue share of 45.4% in 2023, the extensive product offerings from leading manufacturers and their lightweight, portable design, making them suitable for use in remote locations.

• By equipment, hospitals dominated the market and accounted for a share of 41.9% in 2023. The need for efficient patient transport within hospitals and between healthcare facilities is driving the adoption of advanced ambulance stretchers.

Order a free sample PDF of the Ambulance Stretchers Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 2.22 Billion
• 2030 Projected Market Size: USD 2.82 Billion
• CAGR (2024-2030): 3.5%
• North America: Largest market in 2023
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some key companies in ambulance stretchers market include Stryker; Baxter; Medline Industries, LP.; Narang Medical Limited; FU SHUN HSING

TECHNOLOGY CO., LTD; and others. The market players are dedicating significant resources to research and development, driving the introduction of innovative features and technologies that enhance patient safety and comfort during transportation.

• FU SHUN HSING TECHNOLOGY CO., LTD is a manufacturer of innovative medical equipment, including 40 medical transport stretchers and hospital beds. The company’s product range encompasses transfer trolleys, stretchers, lights, and beds for various medical settings, including specialized products for pediatric care. They also offer customizable solutions through OEM and ODM services.

• Ferno-Washington, Inc. is a manufacturer of emergency, mortuary, and healthcare solutions. The company’s comprehensive product range includes ambulance cots, stair chairs, restraints, mattresses, and stretcher accessories, catering to the needs of various healthcare professionals.

Key Players
• Stryker
• Baxter
• Medline Industries, LP.
• Narang Medical Limited
• FU SHUN HSING TECHNOLOGY CO., LTD
• Ferno-Washington, Inc.
• Zhangjiagang New Fellow Med Co.,Ltd.
• ROYAX
• MAC Medical, Inc.
• Advanced Instrumentations

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

Global ambulance stretchers market growth is driven by an increasing geriatric population and a rise in chronic diseases, which heighten the demand for emergency medical services. The prevalence of road accidents further underscores the need for effective stretcher designs, incorporating innovations like telemedicine capabilities and lightweight models for improved patient transport. Additionally, the post-pandemic focus on healthcare emphasizes the importance of well-equipped ambulances, leading to a trend towards eco-friendly stretcher designs that align with sustainability goals. As healthcare systems evolve, the demand for advanced ambulance stretchers is expected to rise.

AI In Life Science Analytics Market: Driving Innovation and Discovery

 The global market for AI in life science analytics was valued at USD 1,731.7 million in 2023 and is expected to grow to USD 3,608.1 million by 2030, reflecting a CAGR of 10.9% from 2024 to 2030. This significant growth is fueled by advancements in AI and machine learning technologies, which have improved the analysis of complex, large-scale datasets, resulting in enhanced drug discovery, personalized medicine, and patient care.

Moreover, increased investments from pharmaceutical companies and government initiatives that promote AI research and development are further driving market growth. AI’s ability to streamline clinical trials, optimize supply chain management, and enhance decision-making processes is accelerating its adoption in the life sciences sector.

Industries within life sciences concentrate on improving health through innovative medical solutions, including drug development, treatments for critical diseases, and minimally invasive surgical tools that enhance patient outcomes and recovery times. Companies are actively pursuing AI innovation in this field. For instance, in October 2023, Fujitsu Limited and RIKEN's HPC- and AI-driven Drug Development Platform Division unveiled a new AI technology capable of predicting protein structural changes from electron microscope images, generating 3D density maps using generative AI.

Key Market Trends & Insights

• In terms of region, North America was the largest revenue generating market in 2023.
• In terms of segment, cloud accounted for a revenue of USD 1,731.7 million in 2023.
• Cloud is the most lucrative delivery segment registering the fastest growth during the forecast period.

Order a free sample PDF of the AI In Life science Analytics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 1,731.7 Million
• 2030 Projected Market Size: USD 3,608.1 Million
• CAGR (2024-2030): 10.9%
• North America: Largest market in 2023

Key Companies & Market Share Insights

The market is extremely competitive, with many companies globally investing in AI-based tools to deliver more effective analytical solutions. For instance, in September 2021, IQVIA introduced the AI-driven MI Contact Center for life sciences. This solution allows companies to disseminate information via new virtual agents, working alongside human experts to prioritize and address inquiries more efficiently.

Key Players

• Indegene
• Lexalytics
• Databricks
• SAS Institute, Inc.
• IQVIA
• IBM
• Sorcero
• Axtria

Browse Horizon Databook for Global AI In Life science Analytics Market Size & Outlook

Conclusion

AI in life science analytics market growth is driven by advancements in AI and machine learning, enhancing drug discovery, personalized medicine, and patient care. Increased investments from pharmaceutical companies and government support for AI research are also contributing to this expansion. Additionally, AI streamlines clinical trials and optimizing supply chain management. Notably, Fujitsu Limited and RIKEN recently introduced AI technology that predicts protein structural changes from electron microscope images, showcasing ongoing innovation in this sector.